Welcome to our dedicated page for Avalon GloboCare SEC filings (Ticker: ALBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalon GloboCare Corp. filings document public-company disclosures for its consumer diagnostics, generative AI software, intellectual property, and capital structure. Recent 8-K reports cover material events involving Avalon Quantum AI LLC, the Catch-Up AI video platform, Nasdaq listing-compliance notices, shareholder communications, and pro forma financial information tied to the completed sale of Avalon RT 9 Properties, LLC.
The company’s proxy and registration filings describe board elections, auditor ratification, equity incentive-plan matters, advisory compensation votes, Nasdaq-rule approvals for warrant share issuance, and securities registration matters. Avalon’s filings also address common stock, warrants, pre-funded warrants, shareholder voting mechanics, governance procedures, operating and financial results, and risk disclosures for a smaller reporting company.
Change Agents Corporation entered into a Business Loan and Security Agreement with a commercial lender on July 24, 2026, obtaining a secured business loan with principal of $825,000. After paying a $41,500 administration fee and repaying in full a $529,400 March 2026 loan from the same lender, net proceeds to the company were $254,350. The company agreed to repay a total of $1,188,000, including $363,000 of interest, in 30 weekly installments of $37,125 beginning July 29, 2026, with a maturity date of March 3, 2027. The loan is evidenced by a Confessed Judgment Secured Promissory Note and secured by a continuing security interest in specified collateral.
Wholly owned subsidiaries Avalon Healthcare System Inc., Avalon Laboratory Services, Inc., and Avalon Quantum AI LLC guaranteed the obligations. The agreement includes restrictive covenants limiting additional debt, investments, liens, asset sales, mergers, affiliate transactions and dividend payments, along with customary representations, covenants and events of default. On the same date, under a Forbearance Letter Agreement, the lender agreed to forbear enforcing payment and default remedies under the March 2026 loan pending the new financing. In consideration, the company issued 360,000 common shares as commitment shares, granted piggyback registration rights on those shares and relied on the Section 4(a)(2) exemption from registration.
Change Agents Corporation entered into an Equity Purchase Agreement with Hudson Global Ventures, giving it the option during a commitment period of up to 36 months to require the investor to buy up to $10,000,000 of common stock. Shares are sold in individual puts between at least $15,000 and at most the lesser of $500,000 and 200% of average daily trading value, at a fixed purchase price of $0.30 per share, subject to anti-dilution adjustments and conditions including an effective resale registration statement, Nasdaq shareholder approval limits, a 4.99% beneficial ownership cap, DWAC eligibility and minimum pricing conditions.
In connection with the equity line, Change Agents issued Hudson a warrant to purchase up to 925,925 shares at an exercise price of $0.01 per share, exercisable after stockholder approval for five years, also subject to a 4.99% beneficial ownership limitation. The company agreed to obtain stockholder approval for the warrant shares within 75 days; failing that, the investor may require a $250,000 cash buyout, upon payment of which the warrant is extinguished. If approval is obtained on time and the five-day average closing price before approval is below $0.27, Change Agents must make a True-Up Payment equal to $250,000 minus the warrant’s value at that price.
A separate Registration Rights Agreement requires filing a resale registration statement within 30 days and using reasonable commercial efforts to have it declared effective within 90 days, remaining effective until all registrable securities are sold and the full commitment is drawn. The warrant and its underlying shares are offered or issuable in reliance on exemptions from Securities Act registration, including Section 4(a)(2) and/or Rule 506(b) of Regulation D.
Change Agents Corporation, formerly Avalon GloboCare Corp., has amended its Delaware charter to change its corporate name, effective July 20, 2026, and will begin trading on The Nasdaq Capital Market under the new ticker CHGA on July 22, 2026. The CUSIP 05344R302 and shareholder rights remain unchanged, and no shareholder action is required.
The company describes a strategic transformation into a pure-play agentic artificial intelligence software business focused on subscription-based applications. Its portfolio includes the Beacon AI Search Optimization platform, the Catch-Up autonomous content-creation platform, and distribution of the FDA-registered KetoAir breathalyzer device, building on its acquisition of RPM Interactive.
Avalon GloboCare Corp. director Lu Wenzhao received a grant of 200,000 options to acquire Avalon GloboCare common stock. The options have an exercise price of $0.2820 per share and expire on June 29, 2029. All 200,000 options vest in full on the grant date, and this grant brings Lu’s reported derivative holdings from this award to 200,000 options held directly.
Avalon GloboCare Corp. director Steven Andrew Sanders received a grant of 200,000 options to purchase common stock. The options have an exercise price of $0.2820 per share and expire on June 29, 2029. According to the terms, all shares subject to the option vest in full on the grant date. Following this award, Sanders holds 202,132 derivative securities directly.
Avalon GloboCare Corp. director Michael Mathews received a grant of 100,000 stock options on June 29, 2026. The options have an exercise price of $0.2820 per share, are fully vested on the grant date, and are exercisable for Common Stock until June 29, 2029. Following this award, he holds 100,000 derivative securities directly.
Avalon GloboCare Corp. reported an equity compensation grant to Interim CEO Li Meng. On June 29, 2026, Meng received options to buy 400,000 shares of common stock at an exercise price of $0.282 per share. According to the terms, 100% of these options vested immediately on the grant date and they expire on June 29, 2029. Following this award, Meng holds 402,000 derivative securities directly.
Avalon GloboCare Corp. reported that Chief Strategy Officer Luisa Ingargiola received a grant of 400,000 stock options on June 29, 2026. The options have an exercise price of $0.2820 per share and expire on June 29, 2029. All shares underlying the option vested in full on the grant date. Following this award, Ingargiola holds 416,000 derivative securities directly.
Avalon GloboCare Corp. director Felix Lourdes reported a compensation-related equity award. He received options to purchase 100,000 shares of common stock on June 29, 2026, at an exercise price of $0.2820 per share. All option shares vested in full on the grant date. Following this grant, Lourdes holds 101,586 derivative option shares directly, which are scheduled to expire on June 29, 2029.
Avalon GloboCare Corp., a Delaware company listed on Nasdaq as “ALBT,” is registering a primary offering of common stock and pre-funded warrants, each sold with accompanying common warrants, plus placement agent warrants. The common warrants become exercisable either after stockholder approval of the warrant shares or immediately if specified Nasdaq “Pricing Conditions” are met, and expire five years after they first become exercisable.
Avalon has pivoted from biotech to a technology-focused model with two segments: an Agentic AI software business (including its Catch-Up short-form video platform and Beacon AI search-visibility product) and a consumer health technology business distributing the Keto Air ketosis breathalyzer in North America. The company reports substantial net losses, an accumulated deficit over $110 million, limited cash, and outstanding indebtedness, leading to substantial doubt about its ability to continue as a going concern absent additional financing.
Avalon also discloses a Nasdaq notice for failing the $1.00 minimum bid price requirement, with an initial 180-day cure period to October 12, 2026, potential further grace periods, and possible delisting if compliance is not regained. The filing highlights significant potential dilution from outstanding preferred stock, options, warrants, and new securities in this offering, as well as legal, regulatory, and commercialization risks around its AI and Keto Air products.